At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Neurologists from multiple clinics shared data at AAIC on the Alzheimer's drug's use, shedding light on its safety and ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

This month, the firm also performed a 1-for-15 reverse share split to maintain compliance with Nasdaq listing requirements.

The financing will in part support development of the firm's PI3K inhibitor paxalisib in PIK3CA-mutated brain cancer and HER2-positive breast cancer.

Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to ...

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...

The partners will seek CAP/CLIA certification for an organoid-based assay and conduct clinical validation studies of it as a tool to guide treatment.

In a Phase II trial, advanced ovarian patients with HRD alterations seemed to fare particularly well on Imunon's IMNN-001 plus standard chemo.